Resveratrol: A therapeutic promise for cardiovascular diseases

Recent Patents on Cardiovascular Drug Discovery

Volumn 2, Issue 2, 2007, Pages 133-138

  Das, Samarjit ^a   Das, Dipak K ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Anti inflammatory effect; Cardioprotection; Phytoestrogen; Polyphenolic antioxidant; Resveratrol; ROS scavenging; Vasodilation

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; APPLE EXTRACT; ASCORBIC ACID; CATECHIN; CURCUMIN; ESTROGEN RECEPTOR; GALLOCATECHIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; GRAPE SEED EXTRACT; GREEN TEA EXTRACT; INDUCIBLE NITRIC OXIDE SYNTHASE; MALONALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PLANT EXTRACT; POLYGONUM CUSPIDATUM EXTRACT; POLYPHENOL DERIVATIVE; PRAVASTATIN; PROCYANIDIN; PROGESTERONE RECEPTOR; PROTYKIN; QUERCETIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; SUPEROXIDE DISMUTASE; THIOCTIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALTERNATIVE MEDICINE; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; APPLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DEATH; CONCENTRATION RESPONSE; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ISOLATION; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; GRAPE; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATENT; PATHOPHYSIOLOGY; POLYGONUM CUSPIDATUM; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RED WINE; REPERFUSION INJURY; REVIEW; RISK FACTOR; RISK REDUCTION;

ANTIOXIDANTS; CARDIOVASCULAR DISEASES; FLAVONOIDS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; PHENOLS; REACTIVE OXYGEN SPECIES; STILBENES; WINE;

EID: 34250756115     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489007780832560     Document Type: Review

References (79)

1. Orallo F. Comparative studies of the antioxidant effects of cis- and trans-resveratrol. Curr Med Chem 2006; 13: 87-98.
2. Rupprich N, Hildebrand H, Kindl H. Substrate specificity in vivo and in vitro in the formation of stilbenes. Biosynthesis of rhaponticin. Arch Biochem Biophys 1980; 200: 72-78.
3. Morelli R, Das S, Bertelli A, et al. The introduction of the stilbene synthase gene enhances the natural antiradical activity of Lycopersicon esculentum mill. Mol Cell Biochem 2006; 282: 65-73.
4. Das S, Das DK. Wine and the Heart: a Journey from Grapes to Resveratrol. S Afr J Enol Vitic 2006; 27: 127-132.
5. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004; 24: 2783-2840.
6. Schubert R, Fischer R, Hain R, et al. An ozone-responsive region of the grapevine resveratrol synthase promoter differs from the basal pathogen-responsive sequence. Plant Mol Biol 1997; 34: 417-426.
7. Celotti E, Ferrarini R, Zironi R, Conte LS. Resveratrol content of some wines obtained from dried Valpolicella grapes: Recioto and Amarone. J Chromatogr A 1996; 730: 47-52.
8. Hain R, Bieseler B, Kindl H, Schroder G, Stocker R. Expression of a stilbene synthase gene in Nicotiana tabacum results in synthesis of the phytoalexin resveratrol. Plant Mol Biol 1990; 15: 325-335.
9. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218-220.
10. Langcake P, Pryce RJ. A now class of phytoalexins from grapevines. Experientia 1977; 33: 151-152.
11. Schoeppner A, Kindl H. Stilbene synthase (pinosylvine synthase) and its induction by ultraviolet light. FEBS Lett 1979; 108: 349-152.
12. Stervbo U, Vang O, Bonnesen C. A review of the content of the putative chemopreventive phytoalexin resveratrol in red wine. Food Chem 2007; 101: 449-457.
13. Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conumdrum of the 'French paradox'? Eur J Endocrinol 1998; 138: 619-620.
14. Hugh J. Vintage: The Story of Wine. Simon and Schuster, Toronto, 1989.
15. Rimm EB, Stampfer MJ. Wine, beer, and spirits: they really horses of a different color?, Circulation 2002; 105: 2806-2807.
16. Gronbaek M, Deis A, Sorensen TIA, Becker U, Schnohr P, Jensen G. Mortality associated with moderate intakes of wine, beer, or spirits, BMJ 1995; 310: 1165-1169.
17. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992; 339: 1523-1526.
18. Hertog MGL, Feskens EJM, Kromhout D. Antioxidant flavonols and coronary heart disease risk. Lancet 1997; 349: 699.
19. Cordova AD, Jacson LAM, Berke-Schlessel DW, Sumpio BE. The Cardiovascular Protective Effect of Red Wine, J Am Coll Surg 2005; 200: 428-439.
20. Soleas GJ, Diamandis EP, Goldberg DM. Wine as a Biological Fluid: History, Production, and Role in Disease Prevention, J Clin Lab Anayl 1997; 11: 287-313.
21. Giampapa, V.C: WO06127759 (2006).
22. Bendheim, P.E., Wein, E.: WO06121985 (2006).
23. Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-κB, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 2000; 164: 6509-6519.
24. Leonard S, Xia C, Jiang BH, et al. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun 2003; 309: 1017-1026.
25. Orallo F, Alvarez E, Camina M, Leiro JM, Gomez E, Fernandez P. The possible implication of trans-resveratrol in the cardioprotective effects of long-term moderate wine consumption. Mol Pharmacol 20021; 61: 294-302.
26. Martinez J, Moreno JJ. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem Pharmacol 2000; 59: 865-870.
27. 3. Free Radic Biol Med 1999; 26: 1531-1537.
28. Hattori R, Otani H, Maulik N, Das DK. Pharmacological preconditioning with resveratrol: role of nitric oxide. Am J Physiol Heart Circ Physiol 2002; 282: H1988-H1995.
29. Gilchrest, B.A., Eller, M.S., Yaar, M., Lee-Bellantoni M.S.: WO06107949 (2006).
30. Lee SK, Mbwambo ZH, Chung H, et al. Evaluation of the antioxidant potential of natural products. Comb Chem High Throughput Screen 1998; 1: 35-46.
31. Kampa M, Hatzoglou A, Notas G, et al. Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. Nutr Cancer 2000; 37: 223-233.
32. Ray PS, Maulik G, Cordis GA, Bertelli AAE, Bertelli A, Das DK. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic Biol Med 1999; 7: 160-169.
33. Ray PS, Maulik G, Cordis GA, et al. Myocardial protection by Protykin, a novel extract of trans-resveratrol and emodin. Free Radic Res 2000; 32: 135-144.
34. Losa GA. Resveratrol modulates apoptosis and oxidation in human blood mononuclear cells. Eur J Clin Invest 2003; 33: 818-823.
35. Olas B, Wachowicz B, Bald E, Glowacki R. The protective effects of resveratrol against changes in blood platelet thiols induced by platinum compounds. J Physiol Pharmacol 2004; 55: 467-476.
36. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 2000; 141: 3657-3667.
37. Yen GC, Duh PD, Lin CW. Effects of resveratrol and 4-hexylresorcicol on hydrogen peroxide-induced oxidative DNA damage in human lymphocytes. Free Radic Res 2003; 37: 509-514.
38. Gehm BD, McAndrews JM, Chien PY, Jameson JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 1997; 94: 14138-14143.
39. Lu R, Serrero G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol 1999; 179: 297-304.
40. Klinge CM, Risinger KE, Watts MB, Beck V, Eder R, Jungbauer A. Estrogenic activity in white and red wine extracts. J Agri Food Chem 2003; 51: 1850-1857.
41. Ashby J, Tinwell H, Pennie W, et al. Partial and weak oestrogenicity of the red wine constituent resveratrol: Consideration of its superagonist activity in MCF-7 cells and its suggested cardiovascular protective effects. J Appl Toxicol 1999; 19: 39-45.
42. Basly JP, Marre-Fournier F, Le Bail JC, Habrioux G, Chulia AJ. Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)- resveratrol. Life Sci 2000; 66: 769-777.
43. Turner RT, Evans GL, Zhang M, Maran A, Sibonga JD. Is resveratrol an estrogen agonist in growing rats? Endocrinology 1999; 140: 50-54.
44. Freyberger A, Hartmann E, Hildebrand H, Krotlinger F. Differential response of immature rat uterine tissue to ethinylestradiol and the red wine constituent resveratrol. Arch Toxicol 2001; 11: 709-715.
45. Mizutani K, Ikeda K, Kawai Y, Yamori Y. Resveratrol attenuates ovariectomy-induced hypertension and bone loss in stroke-prone spontaneously hypertensive rats. J Nutr Sci Vitaminol 2000; 46: 78-83.
46. Levenson AS, Gehm BD, Pearce ST, et al. Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably tranfected with ERα. Int J Cancer 2003; 104: 587-596.
47. Liu J-C, Chen J-J, Chan P, Cheng C-F, Cheng T-H. Inhibition of cyclic strain-induced endothelin-1 gene expression by resveratrol. Hypertension. 2003: 42:1198-1203,
48. Imamura, G, Bertelli A.A, Bertelli A, Otani H, Maulik N, Das DK. Pharmacological preconditioning with resveratrol: an insight with iNOS knockout mice. Am J Physiol Heart Circ Physiol 2002; 282: H1996-2003.
49. Das S, Alagappan VK, Bagchi D, Sharma HS, Maulik N, Das DK. Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption: a potential mechanism for resveratrol preconditioning of the heart. Vascul Pharmacol 2005; 42: 281-289.
50. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM. The red wine phenolics trans-resveratrol and quercitin block human platelet aggregation and eicosanoid synthesis implications for protection against coronary heart disease. Clin Chim Acta 1995; 236: 207-219.
51. Pace-Asciak CR, Rounova O, Hahn SE, Diamandis EP, Goldberg DM. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta 1996; 246: 163-182.
52. Seigneur M, Bonnet J, Dorian B. Effect of the consumption of alcohol, white wine, and red wine on the platelet function and serum lipids. J Appl Cardiol 1990; 5: 215.
53. Demrow HS, Slane PR, Folts JD. Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. Circulation 1995; 91: 1182-1188.
54. Das S, Bertelli AA, Bertelli A, Maulik N, Das DK. Antiinflammatory action of resveratrol: a novel mechanism of action. Arzneimittel Forschung Drug Res 2006; 56: 700-706.
55. Finley, J.W., Mezine, I., Finley, J.W., Gao, S., Hoyt, I., Opet, M.M., Zhang, H.: US2006172012 (2006).
56. Floreani M, Napoli E, Quintieri L, Palatini P. Oral administration of trans-resveratrol to guinera pigs increases cardiac DT- diaphorase and catalase activities, and protects isolated atriafrom menadione, toxicity. Life Sci 2003; 72: 2741-2750.
57. Sato M, Ray PS, Maulik G, Maulik N, Engelman RM, Bertelli AA, Bertelli A, Das DK. Myocardial protection with red wine extract. J Cardiovasc Pharmacol 2000; 35: 263-268.
58. Shigematsu S, Ishida S, Hara M, et al. Resveratrol, a red wine constituent polyphenol, prevents superoxide-dependent inflammatory response induced by ischemia/reperfusion, platelet-activating factor, or oxidants. Free Radic Biol Med 2003; 34: 810-817.
59. Sato M, Maulik G, Bagchi, D, Das DK. Myocardial protection by protykin, a novel extract of trans-resveratrol and emodin. Free Radic Res 2000, 32: 135-144.
60. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36.
61. Bradamente S, Piccinini F, Barenghi L, Bertelli AA, De Jonge R, Beernster P, De Jong JW. Does resveratrol induce pharmacological preconditiong? Int J Tissue React 2000; 22: 1-4.
62. Das S, Cordis GA, Maulik N, Das DK. Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation. Am J Physiol Heart Circ Physiol 2005; 288: H328-35.
63. Das S, Tosaki A, Bagchi D, Maulik N, Das DK. Resveratrol-mediated activation of cAMP response element-binding protein through adenosine A3 receptor by Akt-dependent and -independent pathways. J Pharmacol Exp Ther 2005; 314: 762-769.
64. De Jonge R, Out M, Maas WJ, De Jong JW. Preconditioning of rat hearts by adenosine A1 or A3 receptor activation. Eur J Pharmacol 2002; 441: 165-72.
65. Das S, Fraga CG, Das DK. Cardioprotective effect of resveratrol via HO-1 expression involves p38 map kinase and PI-3-kinase signaling, but does not involve NFkappaB. Free Radic Res 2006; 40: 1066-75.
66. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothetial cells. Biochem Biophys Res Commum 1989; 161: 851-858.
67. Gospodarowicz D, Abraham JA, Schilling J. Isolation and charaterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci USA 1989; 86: 7311-7315.
68. Devries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fins-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989-991.
69. Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187: 1579-86.
70. Kaga, S, Zhan L, Matsumoto M, Maulik N. Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J Mol Cell Cardiol 2005; 39: 813-22.
71. Chen CY, Jang JH, Li MH, Surh YJ. Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. Biochem Biophys Res Commun 2005; 331: 993-1000.
72. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumor growth in vivo. Nature (London) 1993; 362: 841-844.
73. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (London) 1994; 367: 576-579.
74. Penumathsa SV, Thirunavukkarasu M, Koneru S, et al. Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. J Mol Cell Cardiol 2006 (in press).
75. Zou JG, Wang ZR, Huang YZ, Cao KJ, Wu JM. Effect of red wine polyphenol resveratrol on endothelial function in Hypercholesterolemic rabbits Int J Mol Med 2003; 11: 317-320.
76. Gouedard C, Barouki R, Morel Y. Induction of paraoxonase-1 gene expression by resveratrol. Artterios Thromb Vasc Biol 2004; 24: 2378-2383.
77. Pal S. Ho N, Santos C, Dubois P, Mamo J, Croft K, Allister E. Red wine polyphenolics increase LDL receptor expression and activity and suppress the secretion of ApoB100 from human HepG2 cells. J Nutrition 2003; 133: 700-706.
78. Moreno JJ. Resveratrol modulates arachidonic acid release, prostaglandin synthesis, and 3T6 fibroblast growth. J Pharmacol Exp Therapen 2000; 294: 333-338.
79. Olas B, Wachowicz B, Saluk-Juszczak J, Zielinski T. Effect of resveratrol, a natural polyphenolic compound, on platelet activationinduced by endotoxin or thrombin. Thrombosis Res 2002; 107: 141-145.